A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in Adult dengue patients

Journal of Infectious Diseases

Volumn 207, Issue 9, 2013, Pages 1442-1450

  Nguyen, Nguyet Minh ^a   Tran, Chau Nguyen Bich ^a   Phung, Lam Khanh ^a   Duong, Kien Thi Hue ^a   Huynh, Huy Le Anh ^a   Farrar, Jeremy ^a,c   Nguyen, Quyen Than Ha ^a   Tran, Hien Tinh ^a,c   Nguyen, Chau Van Vinh ^b   Merson, Laura ^a   Hoang, Long Truong ^d   Hibberd, Martin L ^d   Aw, Pauline P K ^d   Wilm, Andreas ^d   Nagarajan, Niranjan ^d   Nguyen, Dung Thi ^b   Pham, Mai Phuong ^b   Nguyen, Truong Thanh ^b   Javanbakht, Hassan ^e   Klumpp, Klaus ^e   Hammond, Janet ^e   Petric, Rosemary ^e   Wolbers, Marcel ^a,c   Nguyen, Chinh Tran ^b   Simmons, Cameron P ^a,c   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e HOFFMANN LA ROCHE INC   (United States)

Author keywords

anti viral; clinical trial; Dengue; therapeutics

Indexed keywords

4' AZIDOCYTIDINE; BALAPIRAVIR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; HUMAN; HUMAN CELL; IC 50; IMMUNE RESPONSE; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REPLICATION; VISUAL IMPAIRMENT;

EID: 84875997317     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis470     Document Type: Article

References (16)

1. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of Dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 2009; 80:846-55.
2. Anders KL, Nguyet NM, Chau NV, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011; 84:127-34.
3. Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186:1165-8. (Pubitemid 35177121)
4. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-21. (Pubitemid 34439127)
5. Hoang LT, Lynn DJ, Henn M, et al. The early whole-blood transcriptional signature of dengue and features associated with progression to dengue shock syndrome in vietnamese children and young adults. J Virol 2010; 84:12982-94.
6. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9. (Pubitemid 30049026)
7. Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine 2011; 29:7221-8.
8. Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010; 85:450-62.
9. Tricou V, Minh NN, Van TP, et al. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 2010; 4:e785.
10. Klumpp K, Leveque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006; 281:3793-9. (Pubitemid 43847803)
11. Klumpp K SD. Discovery and clinical evaluation of the nucleoside analog balapiravir (R1626) for the treatment of HCV infection. In: Kazmierski W, ed. Antiviral drugs: from basic discovery through clinical trials hoboken. NJ, USA: John Wiley & Sons, Inc, 2011.
12. Toniutto P, Fabris C, Bitetto D, Fumolo E, Fornasiere E, Pirisi M. R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs 2008; 11:738-49.
13. Roberts SK, Cooksley G, Dore GJ, et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008; 48:398-406.
14. Yap TL, Xu T, Chen YL, et al. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J Virol 2007; 81:4753-65. (Pubitemid 46668672)
15. Hue KD, Tuan TV, Thi HT, et al. Validation of an internally controlled one-step real-time multiplex RT-PCR assay for the detection and quantitation of dengue virus RNA in plasma. J Virol Methods 2011; 177:168-73.
16. Yin Z, Chen YL, Schul W, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106:20435-9.